In last trading session, Keros Therapeutics Inc (NASDAQ:KROS) saw 1.02 million shares changing hands with its beta currently measuring 1.38. Company’s recent per share price level of $11.37 trading at $0.06 or 0.53% at ring of the bell on the day assigns it a market valuation of $460.57M. That closing price of KROS’s stock is at a discount of -542.04% from its 52-week high price of $73.00 and is indicating a premium of 14.07% from its 52-week low price of $9.77. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 3.15 million shares which gives us an average trading volume of 1.44 million if we extend that period to 3-months.
For Keros Therapeutics Inc (KROS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.71. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.43 in the current quarter.
Keros Therapeutics Inc (NASDAQ:KROS) trade information
Upright in the green during last session for gaining 0.53%, in the last five days KROS remained trading in the red while hitting it’s week-highest on Friday, 01/24/25 when the stock touched $11.37 price level, adding 9.47% to its value on the day. Keros Therapeutics Inc’s shares saw a change of -28.17% in year-to-date performance and have moved -0.18% in past 5-day. Keros Therapeutics Inc (NASDAQ:KROS) showed a performance of -32.36% in past 30-days. Number of shares sold short was 4.02 million shares which calculate 2.14 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 100 to the stock, which implies a rise of 88.63% to its current value. Analysts have been projecting 96 as a low price target for the stock while placing it at a high target of 107. It follows that stock’s current price would drop -744.33% in reaching the projected high whereas dropping to the targeted low would mean a loss of -744.33% for stock’s current value.
Keros Therapeutics Inc (KROS) estimates and forecasts
Statistics highlight that Keros Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -78.15% of value to its shares in past 6 months, showing an annual growth rate of 8.85% while that of industry is 16.20. Apart from that, the company came raising its revenue forecast for fiscal year 2025. This year revenue growth is estimated to rise 21,125.47% from the last financial year’s standing.
11 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 37.32M for the same. And 9 analysts are in estimates of company making revenue of 22.23M in the next quarter. Company posted 143k and 83k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -111.11% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 0.22% while estimates for its earnings growth in next 5 years are of 5.74%.
Keros Therapeutics Inc (NASDAQ:KROS)’s Major holders
Insiders are in possession of 2.05% of company’s total shares while institution are holding 100.21 percent of that, with stock having share float percentage of 102.30%. Investors also watch the number of corporate investors in a company very closely, which is 100.21% institutions for Keros Therapeutics Inc that are currently holding shares of the company. FMR LLC is the top institutional holder at KROS for having 4.72 million shares of worth $215.69 million. And as of 2024-06-30, it was holding 16.0279 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 2.51 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.5348 of outstanding shares, having a total worth of $114.86 million.
On the other hand, Vanguard Total Stock Market Index Fund and ACAP Strategic Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 961.35 shares of worth $10.93 million or 2.37% of the total outstanding shares. The later fund manager was in possession of 933.99 shares on Sep 30, 2024 , making its stake of worth around $10.62 million in the company or a holder of 2.31% of company’s stock.
